Divis Nutraceuticals

Hyderabad, India Founded: 2005 • Age: 21 yrs Listed

Manufacture of carotenoid and vitamin ingredients for food, beverage, and nutrition industries.

Page last updated 04 Nov 2026

About Divis Nutraceuticals

Divis Nutraceuticals is a publicly listed company based in Hyderabad (India) founded in 2005. Manufacture of carotenoid and vitamin ingredients for food, beverage, and nutrition industries. It operates in the Consumer and Agriculture sectors. The company has 97 employees. Its Indian entity Divi's Laboratories Limited reported revenue of ₹11,067 Cr. Divis Nutraceuticals offers products and services including Carotenoids and Vitamins. Its focus areas include Food and Agriculture, Nutraceuticals, Ingredient Manufacturing and Carotenoid and Vitamin Production.

Company details

Divis Nutraceuticals is identified as a global manufacturer of high-quality carotenoid and vitamin ingredients that are utilized in the food, beverage, dietary supplement, pet food, and feed sectors. These ingredients, including beta-carotene, astaxanthin, and various vitamins, are incorporated into applications like supplements, dairy, beverages, and animal feed to support health and nutrition goals. Technical expertise in formulation ensures consistent quality and performance across products. Offices are established in multiple countries to facilitate worldwide distribution and innovation in the industry.

Headquarters Hyderabad, India
Employees 97
Stage Public
Sectors
Consumer
Agriculture
Email
••••••••
Phone
•••• ••••
Website divisnutraceuticals.com
Social LinkedIn
Legal Name Divi’S Laboratories Limited
Date of Incorporation 12 Oct, 1990
Jurisdiction Hyderabad, Telangana, India

Operational Areas

Consumer → Food Processing

Agriculture → Animal Feed & Nutrition

Key Metrics

Market Cap
₹3,01,758 Cr
DIVISLAB · NSE
Share Price
₹11,485.00
+1.04% today
Revenue
₹10,560 Cr
FY 2025-26 · +12.8% YoY
EBITDA
₹3,368 Cr
Margin 31.9%
Net Profit
₹2,623 Cr
FY 2025-26 · +19.7% YoY
P/E (TTM)
89.9x
P/B 17.1x
ROE
16.2%
ROCE 21.0%
Employee Count
97

Associated legal entities of Divis Nutraceuticals

Divis Nutraceuticals operates through Divi's Laboratories Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.

Legal entity	Status	Incorporated	Registered in	Revenue (FY 2026)	Employees	Directors	Company page
Divi's Laboratories Limited Listed CIN L24110TG1990PLC011854	Active	12 Oct 1990	Hyderabad, Telangana	₹11,067 Cr	11,560	13	View details

Products & Services of Divis Nutraceuticals

Divis Nutraceuticals offers a comprehensive portfolio of products and services, including Carotenoids and Vitamins.

Carotenoids

Nutraceutical Ingredients

High-quality carotenoids are produced for fortification and coloration in food, supplements, and beverages.

Vitamins

Nutraceutical Ingredients

Vitamins such as A, D3, and E are manufactured for use in human and animal nutrition applications.

Board of directors of Divi's Laboratories Limited (Divis Nutraceuticals)

Divi's Laboratories Limited is the primary company behind Divis Nutraceuticals. The board of Divi's Laboratories Limited currently have 10 directors; the longest-serving is Murali Krishna Prasad Divi, appointed in 1990. 12 earlier directors have ceased.

Director	Designation	Appointed	Tenure	Entity
Murali Krishna Prasad Divi DIN 00005040	Managing Director	12 Oct 1990	36 yrs 1 mo	Divi's Laboratories Limited
Nimmagadda Venkata Ramana DIN 00005031	Whole-time director	01 Oct 1994	32 yrs 1 mo	Divi's Laboratories Limited
Satchandra Kiran Divi DIN 00006503	Whole-time director	10 Aug 2001	25 yrs 3 mo	Divi's Laboratories Limited
Rameshbabu Venkata Nimmagadda DIN 07854042	Director	27 Jun 2017	9 yrs 4 mo	Divi's Laboratories Limited
Nilima Prasad Divi DIN 06388001	Whole-time director	27 Jun 2017	9 yrs 4 mo	Divi's Laboratories Limited
Ganapaty Seru DIN 07872766	Director	22 Jul 2017	9 yrs 3 mo	Divi's Laboratories Limited
Sunaina Singh DIN 08397250	Director	28 Mar 2019	7 yrs 7 mo	Divi's Laboratories Limited
Veerayya Chowdary Kosaraju DIN 08485334	Director	04 Jan 2020	6 yrs 10 mo	Divi's Laboratories Limited
Devendra Rao Sureddy DIN 10481393	Whole-time director	10 Feb 2024	2 yrs 9 mo	Divi's Laboratories Limited
Rajendra Kumar Premchand DIN 00895990	Director	25 May 2024	2 yrs 5 mo	Divi's Laboratories Limited

IPO & Listings of Divis Nutraceuticals

Divis Nutraceuticals is a publicly listed company on the NSE with ticker symbol DIVISLAB in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Listed onNSE: DIVISLAB
Listed entityDivi'S Laboratories Limited
Exchange sectorPharmaceuticals

Financials of Divis Nutraceuticals

Exchange-reported figures of Divi's Laboratories Limited, the listed company behind Divis Nutraceuticals (NSE: DIVISLAB).

Financial Highlights

FY 2025-26 · Consolidated

Revenue

₹10,560 Cr

+12.8% YoY

EBITDA

₹3,368 Cr

+13.4% YoY

Profit After Tax

₹2,623 Cr

+19.7% YoY

Net Worth

₹16,761 Cr

+12.0% YoY

Total Assets

₹17,523 Cr

+17.0% YoY

Total Debt

₹7.00 Cr

+75.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	10,560	9,360	7,845	7,768	8,960	6,969	5,394
Revenue growth	+12.8%	+19.3%	+1.0%	-13.3%	+28.6%	+29.2%	-
EBITDA	3,368	2,969	2,206	2,369	3,883	2,861	1,823
EBITDA margin	+31.9%	+31.7%	+28.1%	+30.5%	+43.3%	+41.1%	+33.8%
Profit before tax	3,388	2,916	2,163	2,369	3,684	2,666	1,819
Net profit	2,623	2,191	1,603	1,824	2,962	1,987	1,335
Net profit margin	+24.8%	+23.4%	+20.4%	+23.5%	+33.1%	+28.5%	+24.8%
EPS (₹)	96.91	82.68	60.38	68.69	111.53	74.75	51.86
Balance sheet
Total assets	17,523	14,973	13,611	12,801	11,759	9,325	7,369
Net worth	16,761	14,969	13,571	12,767	11,728	9,295	7,310
Total debt	7.00	4.00	3.00	3.26	3.69	4.83	38.85
Cash & bank	3,414	3,715	3,980	4,213	2,819	2,156	123
Net working capital	9,055	8,631	8,398	8,211	7,157	5,063	2,816
Cash flow
Cash from operations	2,738	1,653	1,261	2,460	1,912	1,947	1,216
Cash from investing	(2,219)	(804)	(269)	(2,708)	(2,195)	75.13	(83.47)
Cash from financing	(804)	(799)	(799)	(797)	(532)	(34.89)	(1,091)

Particulars	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	3,676	3,080	2,831	2,604	2,715	2,410	2,585	2,319
Revenue growth (YoY)	+35.4%	+27.8%	+9.5%	+12.3%	+16.1%	+13.8%	-	-
Other income	94.00	64.00	155	88.00	145	119	86.00	82.00
EBITDA	1,566	1,255	934	816	888	729	886	743
EBITDA margin	+42.6%	+40.7%	+33.0%	+31.3%	+32.7%	+30.2%	+34.3%	+32.0%
Depreciation	142	133	120	118	113	112	107	99.00
Interest	13.00	6.00	6.00	6.00	8.00	3.00	1.00	0.00
Profit before tax	1,505	1,180	963	780	912	733	864	726
Tax	378	278	212	197	223	188	202	137
Net profit	1,127	902	751	583	689	545	662	589
EPS (₹)	42.49	33.95	28.31	21.98	25.97	20.49	24.93	22.20

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	10,388	9,198	7,665	7,625	8,880	6,799	5,311
Revenue growth	+12.9%	+20.0%	+0.5%	-14.1%	+30.6%	+28.0%	-
EBITDA	3,415	2,980	2,175	2,349	3,878	2,822	1,816
EBITDA margin	+32.9%	+32.4%	+28.4%	+30.8%	+43.7%	+41.5%	+34.2%
Profit before tax	3,436	2,929	2,132	2,354	3,677	2,628	1,813
Net profit	2,662	2,209	1,575	1,805	2,950	1,957	1,331
Net profit margin	+25.6%	+24.0%	+20.6%	+23.7%	+33.2%	+28.8%	+25.1%
EPS (₹)	98.38	83.36	59.47	68.23	111.08	73.64	51.71
Balance sheet
Total assets	17,466	14,897	13,521	12,736	11,718	9,297	7,371
Net worth	16,711	14,895	13,484	12,705	11,691	9,272	7,317
Total debt	0.00	2.00	0.00	0.00	0.00	0.35	33.63
Cash & bank	3,371	3,696	3,961	4,188	2,804	2,142	107
Net working capital	9,015	8,561	8,313	8,157	7,128	5,037	2,821
Cash flow
Cash from operations	2,711	1,650	1,266	2,447	1,910	1,947	1,208
Cash from investing	(2,218)	(803)	(268)	(2,707)	(2,195)	75.34	(81.38)
Cash from financing	(802)	(797)	(798)	(796)	(532)	(33.97)	(1,091)

Particulars	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	3,647	2,974	2,793	2,578	2,660	2,357	2,536	2,297
Revenue growth (YoY)	+37.1%	+26.2%	+10.1%	+12.2%	+15.6%	+14.3%	-	-
Other income	88.00	63.00	154	87.00	146	119	87.00	82.00
Total expenses	2,060	1,734	1,850	1,745	1,765	1,614	1,655	1,550
EBITDA	1,587	1,240	943	833	895	743	881	747
EBITDA margin	+43.5%	+41.7%	+33.8%	+32.3%	+33.6%	+31.5%	+34.7%	+32.5%
Depreciation	142	132	120	116	113	112	107	99.00
Interest	13.00	6.00	6.00	6.00	8.00	3.00	0.00	0.00
Profit before tax	1,520	1,165	971	798	920	747	861	730
Tax	380	274	215	200	224	190	194	136

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 12 Nov 2026

Particulars	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	3,676	3,080	2,831	2,604	2,715	2,410	2,585	2,319
Revenue growth (YoY)	+35.4%	+27.8%	+9.5%	+12.3%	+16.1%	+13.8%	-	-
Other income	94.00	64.00	155	88.00	145	119	86.00	82.00
EBITDA	1,566	1,255	934	816	888	729	886	743
EBITDA margin	+42.6%	+40.7%	+33.0%	+31.3%	+32.7%	+30.2%	+34.3%	+32.0%
Depreciation	142	133	120	118	113	112	107	99.00
Interest	13.00	6.00	6.00	6.00	8.00	3.00	1.00	0.00
Profit before tax	1,505	1,180	963	780	912	733	864	726
Tax	378	278	212	197	223	188	202	137
Net profit	1,127	902	751	583	689	545	662	589
EPS (₹)	42.49	33.95	28.31	21.98	25.97	20.49	24.93	22.20

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	10,560	9,360	7,845	7,768	8,960	6,969	5,394
Revenue growth	+12.8%	+19.3%	+1.0%	-13.3%	+28.6%	+29.2%	-
Other income	507	352	339	345	114	62.56	190
Total expenses	7,192	6,391	5,639	5,398	5,077	4,108	3,571
Employee cost	1,442	1,243	1,094	975	946	826	621
EBITDA	3,368	2,969	2,206	2,369	3,883	2,861	1,823
EBITDA margin	+31.9%	+31.7%	+28.1%	+30.5%	+43.3%	+41.1%	+33.8%
Depreciation	463	402	378	343	312	256	186
Interest	24.00	3.00	4.00	1.96	2.00	2.10	7.14
Profit before tax	3,388	2,916	2,163	2,369	3,684	2,666	1,819
Tax	820	725	563	545	723	682	443
Net profit	2,623	2,191	1,603	1,824	2,962	1,987	1,335
Net profit margin	+24.8%	+23.4%	+20.4%	+23.5%	+33.1%	+28.5%	+24.8%
EPS (₹)	96.91	82.68	60.38	68.69	111.53	74.75	51.86

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	53.00	53.00	53.00	53.09	53.09	53.09	53.09
Reserves & surplus	16,708	14,916	13,518	12,714	11,675	9,242	7,257
Shareholders' funds (net worth)	16,761	14,969	13,571	12,767	11,728	9,295	7,310
Minority interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Secured loans	0.00	2.00	0.00	0.00	0.00	0.35	33.63
Unsecured loans	7.00	2.00	3.00	3.26	3.69	4.48	5.22
Total debt	7.00	4.00	3.00	3.26	3.69	4.83	38.85
Total liabilities	17,523	14,973	13,611	12,801	11,759	9,325	7,369
Assets
Gross block	9,413	7,868	6,760	6,365	5,624	4,692	3,514
Net block	6,528	5,442	4,739	4,723	4,325	3,704	2,782
Capital work in progress	2,113	1,022	778	212	470	711	920
Investments	69.00	65.00	82.00	77.05	72.01	0.01	971
Inventories	3,954	3,236	3,184	3,000	2,829	2,145	1,864
Sundry debtors	2,984	2,731	2,156	1,793	2,424	1,677	1,413
Cash & bank balances	3,414	3,715	3,980	4,213	2,819	2,156	123
Loans & advances	744	399	355	306	280	197	309
Total current assets	11,096	10,081	9,675	9,312	8,352	6,175	3,708
Total current liabilities	2,041	1,450	1,277	1,101	1,195	1,111	892
Net working capital	9,055	8,631	8,398	8,211	7,157	5,063	2,816
Total assets	17,523	14,973	13,611	12,801	11,759	9,325	7,369

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	413	363	170	1,215	2,030	43.15	2.10
Net cash from operating activities	2,738	1,653	1,261	2,460	1,912	1,947	1,216
Net cash from investing activities	(2,219)	(804)	(269)	(2,708)	(2,195)	75.13	(83.47)
Net cash from financing activities	(804)	(799)	(799)	(797)	(532)	(34.89)	(1,091)
Net change in cash	(285)	50.00	193	(1,045)	(816)	1,987	41.05
Closing cash	3,414	3,715	3,980	4,213	2,819	2,156	123

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	+12.8%	+19.3%	+1.0%	-13.3%	+28.6%	+29.2%	-
EBITDA growth	+13.4%	+34.6%	-6.9%	-39.0%	+35.7%	+56.9%	-
PBT growth	+16.2%	+34.8%	-8.7%	-35.7%	+38.2%	+46.5%	-1.9%
Net income growth	+19.7%	+36.7%	-12.1%	-38.4%	+49.1%	+48.8%	-
Revenue CAGR (3Y)	+10.8%	+1.5%	+4.0%	+12.9%	+21.9%	+21.4%	+9.9%
EBITDA CAGR (3Y)	+12.4%	-8.6%	-8.3%	+9.1%	+27.5%	+31.3%	+8.0%
Profitability & leverage
Net income margin	+24.3%	+23.4%	+20.4%	+23.5%	+33.0%	+28.5%	+25.5%
Return on capital employed	+21.0%	+20.4%	+16.4%	+19.3%	+35.0%	+32.0%	+25.3%
Return on net worth	+16.2%	+15.4%	+12.2%	+14.9%	+28.2%	+23.9%	+19.3%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Long-term debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest cover	0.83	0.12	0.22	0.10	0.06	0.08	0.44
Efficiency & per share
Fixed asset turnover	1.22	1.28	1.20	1.30	1.74	1.70	1.75
Inventory turnover	2.94	2.92	2.54	2.67	3.60	3.48	2.97
Debtors turnover	3.70	3.83	3.97	3.68	4.37	4.51	4.19
EPS (₹)	96.91	82.68	60.38	68.69	111.53	74.75	51.86
Dividend per share (₹)	30.00	30.00	30.00	30.00	30.00	20.00	16.00
Book value per share (₹)	632.49	564.87	512.11	480.96	441.82	350.15	275.38

Particulars	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Revenue	3,647	2,974	2,793	2,578	2,660	2,357	2,536	2,297
Revenue growth (YoY)	+37.1%	+26.2%	+10.1%	+12.2%	+15.6%	+14.3%	-	-
Other income	88.00	63.00	154	87.00	146	119	87.00	82.00
Total expenses	2,060	1,734	1,850	1,745	1,765	1,614	1,655	1,550
EBITDA	1,587	1,240	943	833	895	743	881	747
EBITDA margin	+43.5%	+41.7%	+33.8%	+32.3%	+33.6%	+31.5%	+34.7%	+32.5%
Depreciation	142	132	120	116	113	112	107	99.00
Interest	13.00	6.00	6.00	6.00	8.00	3.00	0.00	0.00
Profit before tax	1,520	1,165	971	798	920	747	861	730
Tax	380	274	215	200	224	190	194	136

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	10,388	9,198	7,665	7,625	8,880	6,799	5,311
Revenue growth	+12.9%	+20.0%	+0.5%	-14.1%	+30.6%	+28.0%	-
Other income	506	352	337	349	111	62.53	190
Total expenses	6,973	6,218	5,490	5,276	5,002	3,977	3,494
Employee cost	1,400	1,210	1,067	953	927	809	608
EBITDA	3,415	2,980	2,175	2,349	3,878	2,822	1,816
EBITDA margin	+32.9%	+32.4%	+28.4%	+30.8%	+43.7%	+41.5%	+34.2%
Depreciation	461	401	376	342	311	255	186
Interest	24.00	2.00	4.00	2.00	1.73	1.81	7.03
Profit before tax	3,436	2,929	2,132	2,354	3,677	2,628	1,813
Tax	829	720	556	546	728	673	441
Net profit	2,662	2,209	1,575	1,805	2,950	1,957	1,331
Net profit margin	+25.6%	+24.0%	+20.6%	+23.7%	+33.2%	+28.8%	+25.1%
EPS (₹)	98.38	83.36	59.47	68.23	111.08	73.64	51.71

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	53.00	53.00	53.00	53.00	53.09	53.09	53.09
Reserves & surplus	16,658	14,842	13,431	12,652	11,638	9,218	7,264
Shareholders' funds (net worth)	16,711	14,895	13,484	12,705	11,691	9,272	7,317
Secured loans	0.00	2.00	0.00	0.00	0.00	0.35	33.63
Unsecured loans	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total debt	0.00	2.00	0.00	0.00	0.00	0.35	33.63
Total liabilities	17,466	14,897	13,521	12,736	11,718	9,297	7,371
Assets
Gross block	9,397	7,859	6,752	6,358	5,618	4,685	3,508
Net block	6,520	5,440	4,737	4,719	4,321	3,699	2,776
Capital work in progress	2,113	1,022	778	212	470	711	920
Investments	76.00	72.00	89.00	84.00	79.37	7.37	979
Inventories	3,711	3,033	2,985	2,781	2,644	2,043	1,744
Sundry debtors	3,228	2,855	2,273	1,964	2,570	1,746	1,533
Cash & bank balances	3,371	3,696	3,961	4,188	2,804	2,142	107
Loans & advances	724	395	353	303	278	195	305
Total current assets	11,034	9,979	9,572	9,236	8,296	6,125	3,690
Total current liabilities	2,019	1,418	1,259	1,079	1,168	1,089	869
Net working capital	9,015	8,561	8,313	8,157	7,128	5,037	2,821
Total assets	17,466	14,897	13,521	12,736	11,718	9,297	7,371

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	394	344	144	1,200	2,016	27.88	(7.96)
Net cash from operating activities	2,711	1,650	1,266	2,447	1,910	1,947	1,208
Net cash from investing activities	(2,218)	(803)	(268)	(2,707)	(2,195)	75.34	(81.38)
Net cash from financing activities	(802)	(797)	(798)	(796)	(532)	(33.97)	(1,091)
Net change in cash	(309)	50.00	200	(1,056)	(817)	1,988	35.84
Closing cash	3,371	3,696	3,961	4,188	2,804	2,142	107

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	+12.9%	+20.0%	+0.5%	-14.1%	+30.6%	+28.0%	-
EBITDA growth	+14.6%	+37.0%	-7.4%	-39.4%	+37.4%	+55.4%	-
PBT growth	+17.3%	+37.4%	-9.4%	-36.0%	+39.9%	+44.9%	-1.1%
Net income growth	+20.5%	+40.2%	-12.7%	-38.8%	+50.7%	+47.0%	-
Revenue CAGR (3Y)	+10.9%	+1.2%	+4.1%	+12.8%	+22.1%	+21.2%	+9.7%
EBITDA CAGR (3Y)	+13.3%	-8.4%	-8.3%	+9.0%	+28.0%	+31.1%	+8.1%
Profitability & leverage
Net income margin	+25.1%	+24.0%	+20.6%	+23.7%	+33.2%	+28.8%	+25.9%
Return on capital employed	+21.4%	+20.6%	+16.3%	+19.3%	+35.0%	+31.6%	+25.2%
Return on net worth	+16.5%	+15.6%	+12.0%	+14.8%	+28.1%	+23.6%	+19.2%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Long-term debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest cover	0.81	0.08	0.22	0.10	0.05	0.07	0.43
Efficiency & per share
Fixed asset turnover	1.20	1.26	1.17	1.27	1.72	1.66	1.73
Inventory turnover	3.08	3.06	2.66	2.81	3.79	3.59	3.12
Debtors turnover	3.42	3.59	3.62	3.36	4.12	4.15	3.77
EPS (₹)	98.38	83.36	59.47	68.23	111.08	73.64	51.71
Dividend per share (₹)	30.00	30.00	30.00	30.00	30.00	20.00	16.00
Book value per share (₹)	630.60	562.08	508.83	479.43	440.44	349.28	275.63

Top companies in Food Processing

2 companies that operate in the same segment as Divis Nutraceuticals (Food Processing) in India, ranked by their profile score on The Company Check.

Company	Description	Founded	Location	Total funding	Revenue	Employees
Sahyadri Farms	Fruits and vegetables processing services are provided by Sahyadri Farms.	2011	Nashik, Maharashtra, India	USD 84.86 M	USD 225.11 M	1,472
Varun Beverages	Brand of beverage products	1995	Gurugram, Haryana, India	USD 133 M	USD 2.33 B	12,570

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.

Included in your Premium account

✓
Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
✓
Full access to every database India & global coverage, advanced filters and rich profile details
✓
Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Divis Nutraceuticals

DIVISLAB: RS. 57.54 CRORES NSE BLOCK TRADE; FOR ~ 50,581 SHARES, AT RS. 11375.00

Exchange Update • 2 days ago

Divi's Labs: Management Confirms Double-Digit Revenue Growth Outlook For The Second Half Of FY2027, While Not Specifying A More Exact Percentage Beyond The 17% Constant Currency Growth Seen In The First Half.

Exchange Update • 4 days ago

DIVISLAB: Q2 EBITDA 15.66B RUPEES VS 8.88B (YOY); Q2 EBITDA MARGIN 42.60% VS 32.71% (YOY)

Exchange Update • 6 days ago

DIVISLAB: Q2 CONS NET PROFIT 11.27B RUPEES VS 6.89B (YOY) || Q2 REVENUE 36.76B RUPEES VS 27.15B (YOY)

Exchange Update • 6 days ago

DIVISLAB: RS. 63.94 CRORES BSE BLOCK TRADE; FOR ~ 72,121 SHARES, AT RS. 8865.00

Exchange Update • 21 days ago

DIVISLAB: RS. 90.52 CRORES NSE BLOCK TRADE; FOR ~ 99,986 SHARES, AT RS. 9053.00

Exchange Update • 22 days ago

DIVISLAB: RS. 194.80 CRORES NSE BLOCK TRADE; FOR ~ 213,394 SHARES, AT RS. 9128.50

Exchange Update • 22 days ago

Divi’s Labs, TVS Motor Emerge As Nifty Inclusion Contenders, Up To $824 Million Inflows In Sight

Exchange Update • 1 month ago

DIVISLAB: Rs. 23.49 Crores BSE Block Trade; for ~ 24,994 Shares, at Rs. 9400.00

Exchange Update • 1 month ago

Divis Laboratories Ltd down for fifth straight session | Capital Market News - Business Standard

Business Standard • 1 month ago

Premium access

Complete news archive for Divis Nutraceuticals

Full article history, source details, and older brand coverage require an active premium plan.

Full article archive
Source and publication date
Older coverage
Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Divis Nutraceuticals

When was Divis Nutraceuticals founded?

Divis Nutraceuticals was founded in 2005.

Where is Divis Nutraceuticals located?

Divis Nutraceuticals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

How many employees does Divis Nutraceuticals have?

Divis Nutraceuticals has 97 employees.

What is the annual revenue of Divis Nutraceuticals?

The primary company behind Divis Nutraceuticals, Divi's Laboratories Limited, reported revenue of ₹11,067 Cr for FY 2026, up 13% year on year.

What does Divis Nutraceuticals do?

What products or services does Divis Nutraceuticals offer?

Divis Nutraceuticals offers Carotenoids and Vitamins.

Is Divis Nutraceuticals publicly traded?

Yes, Divis Nutraceuticals is publicly traded on NSE under the ticker symbol DIVISLAB.

Which legal entities are associated with Divis Nutraceuticals?

Divis Nutraceuticals operates through Divi's Laboratories Limited.

Who are the directors of Divis Nutraceuticals?

The legal entities of Divis Nutraceuticals currently have 12 directors, including Sunaina Singh, Rameshbabu Venkata Nimmagadda, Satish Choudhury Meka and others.